ABT-869 inhibits the proliferation of ewing sarcoma cells and suppresses platelet-derived growth factor receptor β and c-KIT signaling pathways

Molecular Cancer Therapeutics

Volumn 9, Issue 3, 2010, Pages 653-660

  Ikeda, Alan K ^a   Judelson, Dejah R ^a   Federman, Noah ^a   Glaser, Keith B ^c   Landaw, Elliot M ^a   Denny, Christopher T ^a,b   Sakamoto, Kathleen M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN A4573; CELL STRAIN TC71; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EWING SARCOMA; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VIVO STUDY; LABELING INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SARCOMA CELL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; INDAZOLES; MICE; MICE, INBRED NOD; MICE, SCID; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SARCOMA, EWING'S; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949740524     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0812     Document Type: Article

References (18)

1. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001;20:5747-54.
2. Denny C. Defining small round cell tumors of childhood: when is a rose really a rose. J Pediatr Hematol Oncol 2001;23:338-9.
3. Potikyan G, France KA, Carlson MR, Dong J, Nelson SF, Denny CT. Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors. Lab Invest 2008.
4. Potikyan G, Savene RO, Gaulden JM, et al. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Res 2007;67:6675-84.
5. Rodriguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007;110:375-84.
6. Iwamoto Y. Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol 2007;37:79-89.
7. Kontny U. Regulation of apoptosis and proliferation in Ewing's sarcoma-opportunities for targeted therapy. Hematol Oncol 2006;24:14-21.
8. Lambert G, Bertrand JR, Fattal E, et al. EWS fli-1 antisense nano-capsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 2000;279:401-6.
9. Uren A, Tcherkasskaya O, Toretsky JA. Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry 2004;43:13579-89.
10. Uren A, Merchant MS, Sun CJ, et al. β-Platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003;22:2334-42.
11. Gonzalez I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004;10:751-61.
12. Bozzi F, Tamborini E, Negri T, et al. Evidence for activation of KIT, PDGFRá, and PDGFRβ receptors in the Ewing sarcoma family of tumors. Cancer 2007;109:1638-45.
13. Hotfilder M, Lanvers C, Jurgens H, Boos J, Vormoor J. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemother Pharmacol 2002;50:167-9.
14. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-9.
15. Druker BJ. Taking aim at Ewing's sarcoma: Is KIT a target and will imatinib work? J Natl Cancer Inst 2002;94:1660-1.
16. Shankar DB, Li J, Tapang P, et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007;109: 3400-8.
17. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006;5:995-1006.
18. Andersson MK, Aman P. Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Cancer Cell Int 2008;8:1.